Prescription RequiredBevacizumab 400 mg/16 mL (Bryxta) Injection is a targeted anticancer medicine used to treat various advanced and metastatic cancers, including colorectal, lung, kidney, ovarian, cervical, and brain cancers. It is administered as an intravenous infusion under medical supervision and works by blocking the formation of new blood vessels that supply nutrients to tumours, helping slow their growth.
| Generic name | Bevacizumab |
| Strength | 400 mg |
| Manufacturer | Zydus Cadila |
| Package size | 1 vial |
| Used for | Colorectal, lung, kidney, ovarian, cervical, and brain cancers |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), a protein responsible for forming new blood vessels. By preventing new blood vessel growth, it reduces the tumour’s supply of oxygen and nutrients, helping slow or stop cancer growth.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.
